Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Some statements align with the label’s key safety themes for colchicine (GI adverse reactions; neuromuscular toxicity; CYP3A4/P-gp interaction mechanism; renal impairment toxicity; contraindication with dual CYP3A4/P-gp inhibitors in renal/hepatic impairment). However, multiple claims are not sufficiently supported by the provided label excerpts (e.g., bone-marrow toxicity, specific lists of interaction drug classes such as “heart and blood-pressure medications” and “certain antibiotics/antifungals,” prophylaxis- vs flare-dose framing, and claims about urgency guidance). Several dosing-related and frequency/risk phrasing elements are also broader than the supplied label text.
Category Scores
Accurate Statements
Colchicine safety concerns include dose-related toxicity.
Supported only in part by label language that GI symptoms are early signs of toxicity and may indicate dose needs reduction/therapy stop; dose relationship is consistent but the provided excerpt does not explicitly phrase “dose-related toxicity” as such.
Colchicine safety concerns include drug–drug interactions.
Label drug interaction toxicity is emphasized via CYP3A4/P-gp substrate status and fatal interactions (Drug Interactions section).
Colchicine safety concerns are greater in people with kidney or liver problems.
Renal impairment is associated with colchicine toxicity; contraindications specify renal/hepatic impairment constraints for dual inhibitors. Hepatic-specific excerpt beyond contraindication is not shown, but renal/hepatic relevance is supported via contraindications.
Colchicine can cause gastrointestinal side effects such as diarrhea, nausea, and vomiting.
Adverse reactions list includes diarrhea, nausea, vomiting (and abdominal pain) as GI disorders.
Colchicine can cause neuromuscular toxicity.
Warnings note colchicine-induced neuromuscular toxicity and rhabdomyolysis reported; adverse reactions section mentions neuromuscular toxicity.
Bone-marrow and neuromuscular toxicity are rare.
Neuromuscular toxicity is described in warnings as reported with chronic treatment; rarity/combined rarity phrasing is not directly supported by the provided excerpts.
Colchicine has clinically important interactions with drugs that inhibit pathways involved in colchicine clearance.
Label: colchicine is substrate of CYP3A4 and P-gp; inhibition of these pathways may lead to toxicity.
Using colchicine with strong inhibitors can raise colchicine exposure.
Label states dual inhibition produces significant increases in systemic colchicine levels and toxicity.
Colchicine interactions are especially relevant with other agents that can inhibit CYP3A4 and/or P-glycoprotein.
Label details interactions with inhibitors of CYP3A4 and/or P-gp; clarithromycin as dual inhibitor is specifically highlighted.
To improve colchicine safety, use only the exact dose and duration prescribed for flare treatment.
Label supports that GI disorders are first signs of toxicity and may indicate dose reduction or therapy stop, and contraindication/interaction guidance implies regimen adherence; however exact wording about “duration prescribed for flare treatment” is not explicitly in excerpts.
To improve colchicine safety, do not combine colchicine with interacting drugs without checking first.
Label advises avoiding concomitant use with dual CYP3A4/P-gp inhibitors in appropriate contraindicated settings and reduced daily dose/monitoring if necessary; “without checking first” is not explicit.
If colchicine is unsafe due to interactions, kidney/liver function, or intolerance, acute gout is often treated with NSAIDs.
Not supported by the provided label excerpts. (Included here only as a partial/weak mapping to “if treatment with colchicine is necessary, reduced dose… and closely monitored”; no NSAID alternative is described in the supplied label text.)
Unsupported Statements
Colchicine is commonly used to treat acute gout attacks.
Label excerpt provided is for prophylaxis of gout flares in adults; no label support for acute attack treatment is included.
Colchicine can cause bone-marrow toxicity.
Provided label excerpts do not mention bone-marrow toxicity.
Bone-marrow and neuromuscular toxicity are rare.
No rarity statements for bone-marrow toxicity, nor explicit rarity for neuromuscular toxicity, appear in the supplied excerpts.
Bone-marrow and neuromuscular toxicity are more likely with excessive dosing.
The provided excerpts do not state this relationship for bone-marrow and neuromuscular toxicity with excessive dosing.
Bone-marrow and neuromuscular toxicity are more likely with interacting drugs.
Label supports increased risk with certain interactions for toxicity in general, but the specific claim about neuromuscular toxicity being “more likely” with interacting drugs is not explicitly supported by the provided excerpt.
Colchicine can cause serious toxicity in people with reduced kidney function.
Renal impairment is associated with colchicine toxicity and dose reduction/alternatives should be considered for severe renal impairment; however the excerpt does not phrase “serious toxicity” or quantify seriousness.
Reduced kidney function or liver disease can lead to slower clearance of colchicine.
The provided excerpts discuss decreased urinary clearance and excretion-related effects for renal impairment, but do not explicitly describe “slower clearance” in both kidney and liver disease.
Colchicine risks are more relevant when colchicine is taken at higher flare doses.
The supplied label excerpts provide prophylaxis dosing (0.6 mg once or twice daily; max 1.2 mg/day) but do not support “higher flare doses” framing.
Colchicine risks are more relevant when patients continue colchicine longer than intended.
The supplied excerpts do not explicitly state that prolonged continuation beyond intended duration increases risk.
Colchicine safety is strongly affected by kidney function.
The label supports increased toxicity with severe renal impairment and need for dose reduction/alternatives; “strongly affected” is not an exact label phrase and is not directly quantified.
In patients with impaired renal clearance, the same colchicine dose can lead to higher blood levels.
The provided renal impairment excerpt discusses decreased urinary clearance and toxicity; it does not explicitly state “higher blood levels” for renal impairment at a given dose.
Higher blood levels of colchicine increase the chance of adverse effects.
The excerpts explicitly state increased systemic levels with dual inhibitors, but do not explicitly generalize to all renal impairment adverse effects.
Clinicians typically use lower doses in patients with impaired renal or hepatic clearance.
Renal impairment excerpt supports dose reduction/alternatives in severe renal impairment. Hepatic-specific dose adjustment text is not provided in the supplied excerpts.
Clinicians may avoid colchicine in more severe impairment.
The label excerpt supports considering alternatives and dose reduction for severe renal impairment, but “clinicians may avoid” is not a direct label statement.
Colchicine interactions are especially relevant with some antibiotics and antifungals.
The provided excerpts do not name antibiotics/antifungals in general; only clarithromycin is explicitly mentioned.
Colchicine interactions are especially relevant with certain antivirals.
No antivirals are identified in the provided excerpts.
Colchicine interactions are especially relevant with some heart and blood-pressure medications.
No heart/blood-pressure medications are identified in the provided excerpts.
Raising colchicine exposure increases the likelihood of dangerous toxicity.
The excerpt states fatal toxicity with dual inhibitors due to significant increases in systemic levels; “likelihood” phrasing is broader than the label’s described fatality outcomes.
Colchicine should be approached with extra caution or avoided in multiple interacting medications that could raise colchicine levels.
The label provides specific contraindication with dual CYP3A4/P-gp inhibitors in renal/hepatic impairment and guidance for reduced daily dose/monitoring if necessary. “Extra caution or avoided” for “multiple interacting medications” is not explicitly supported.
Colchicine should be approached with extra caution or avoided in conditions where monitoring is difficult.
No such monitoring difficulty caution is included in the supplied excerpts.
If colchicine is unsafe, acute gout is often treated with corticosteroids.
The provided label excerpts do not discuss alternative treatments for acute gout when colchicine is unsafe.
Corticosteroids may be given orally, intramuscularly, or intra-articularly depending on the joint.
No corticosteroid route guidance is present in the supplied excerpts.
In some cases, acute gout is treated with targeted biologic or other specialty options for special situations.
No label support in the provided excerpts for biologic/specialty alternatives.
Seeking urgent help is recommended if severe diarrhea/vomiting occurs while taking colchicine.
No urgent/help-seeking instruction is contained in the supplied label excerpts.
Seeking urgent help is recommended if unusual muscle weakness occurs while taking colchicine.
No urgent/help-seeking instruction is contained in the supplied label excerpts.
Seeking urgent help is recommended if numbness/tingling occurs while taking colchicine.
No numbness/tingling symptom guidance is included in the supplied label excerpts.
Seeking urgent help is recommended if signs of dehydration occur while taking colchicine.
No dehydration-sign guidance is included in the supplied label excerpts.
Contradictions
Low
AI Statement
Colchicine is commonly used to treat acute gout attacks.
Label Reference
Indications section provided indicates prophylaxis of gout flares in adults; the label excerpts supplied do not support acute attack treatment use.
Important Omissions
FDA-labeled dosing for the stated population/indication (prophylaxis of gout flares in adults) including explicit dosing schedule (0.6 mg once or twice daily) and maximum dose (1.2 mg/day) is not reflected in several safety/risk statements that discuss “flare doses” rather than the label’s prophylaxis regimen.
Importance:
Moderate
Label contraindication details: patients with both renal and hepatic impairment should not be given GLOPERBA, and contraindication specifically for use in renal/hepatic impairment with drugs that inhibit both CYP3A4 and P-gp is not clearly stated in the provided claims list.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While key label-supported risks (GI toxicity, neuromuscular toxicity, CYP3A4/P-gp interaction with fatal toxicity under dual inhibition, and renal impairment association with toxicity) are addressed, several statements introduce unsupported adverse effects (bone-marrow toxicity), broad/unspecified interaction drug class claims, and non-label urgent care instructions. Unsupported guidance about symptoms requiring urgent help and non-labeled treatment alternatives could mislead users if treated as label-accurate.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are not supported by the provided label excerpts (notably bone-marrow toxicity, specific interaction drug classes, urgent help symptom guidance, and acute gout/corticosteroid/biologic alternatives). Some safety/risk framing is broader or differently targeted than the label’s prophylaxis indication and labeled dosing.
Suggested Improvement
Restrict claims to label-supported items in the provided excerpts: prophylaxis indication; labeled dosing (0.6 mg once or twice daily; max 1.2 mg/day); GI adverse reactions (diarrhea, nausea, vomiting, abdominal pain); neuromuscular toxicity and risk factors as described; interaction mechanism and the specific contraindication language for dual CYP3A4/P-gp inhibitors in renal/hepatic impairment; renal impairment dose reduction/monitoring concepts. Remove or qualify unsupported items (bone-marrow toxicity, specific antibiotic/antifungal/antiviral/heart-med examples, urgent help triggers, and acute gout alternative therapies not present in the supplied label excerpts).